Atossa Therapeutics, INC.
SEC CIK 1488039 · ATOS · last insider filing 2026-05-14
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Steinhart Richard I | Director | filed 2014 - 2026 |
| Remmel H. Lawrence | Director | filed 2012 - 2026 |
| Galli Stephen J | Director | filed 2012 - 2026 |
| Chen Shu-Chih | Director · Chief Scientific Officer | filed 2012 - 2026 |
| Finn Jonathan | Director | filed 2023 - 2026 |
| Cigler Tessa | Director | filed 2024 - 2026 |
| Quay Steven C | Director · President and CEO | filed 2012 - 2026 |
| Weaver Gregory L | Director · Former EVP, CFO, & Director | filed 2013 - 2023 |
| Cross Alexander D | Director | filed 2012 - 2013 |
| Barnhart John | Director | filed 2012 - 2013 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Daniel Mark James | Chief Financial Officer | filed 2025 - 2026 |
| Rees Heather | SVP, Finance and Accounting | filed 2023 - 2025 |
| Guse Kyle | See Remarks | filed 2013 - 2023 |
| Youmans Scott | Chief Operating Officer | filed 2015 - 2015 |
| Sawyer John E | Senior Vice President | filed 2014 - 2015 |
| Destro Christopher S. | Sr. VP, Sales and Marketing | filed 2014 - 2015 |
| Carbonaro Peter J. | Sr. Vice President, Operations | filed 2014 - 2014 |
| Chen Ben R | Sr. VP of Glob. Reg. Affairs | filed 2014 - 2014 |
| Benjamin Christopher | Chief Financial Officer | filed 2012 - 2012 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.